Literature DB >> 6602000

Stimulation of different pathways of T-cell functions by syngeneic tumor cells and soluble membrane proteins.

M Bertschmann, E F Lüscher.   

Abstract

Cells from the draining lymph nodes of DBA/2 mice bearing syngeneic intradermal P-815 tumors represent an excellent responding cell population for secondary stimulation in vitro, despite the virtual absence of response by spleen cells of the same animals. Cytotoxicity is a result of stimulation with intact mitomycin-treated tumor cells. Isolated tumor cell membranes, in the form of small vesicles, stimulated cytotoxicity to a very limited extent and inhibited the development of cytotoxic T lymphocytes over a wide range of concentrations. Membrane proteins solubilized with deoxycholate and papain had only a suppressive effect. Soluble proteins exerted their effect during the induction of cytotoxic T lymphocytes and were ineffective when present during the effector phase of cytotoxic T lymphocytes. The suppressive capacity was shown to reside in a cell population which was sensitive to treatment with monoclonal Lyt-2.1 antibody and complement but not with Lyt-1.1 antibody. This phenotype was compatible with a specific rather than a promiscuous type of suppressor effector cell.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602000     DOI: 10.1016/0008-8749(83)90255-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells.

Authors:  J K Steele; D Liu; A T Stammers; S Whitney; J G Levy
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Proliferative patterns of lymphocytes in lymph nodes during tumour development: involvement of T and B cell areas.

Authors:  M Bertschmann; R Markwalder-Hartenbach; E Pedrinis; M W Hess; H Cottier
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.